[C:1]([C:4]1[N:5]([C:14]2[CH:19]=[CH:18][C:17]([NH2:20])=[CH:16][CH:15]=2)[C:6]2[C:11]([CH:12]=1)=[CH:10][C:9]([NH2:13])=[CH:8][CH:7]=2)(=[O:3])[CH3:2].[CH3:21][N:22]([CH3:32])[C:23]1[CH:31]=[CH:30][C:26]([C:27]([O-])=[O:28])=[CH:25][CH:24]=1>>[C:1]([C:4]1[N:5]([C:14]2[CH:19]=[CH:18][C:17]([NH:20][C:27](=[O:28])[C:26]3[CH:30]=[CH:31][C:23]([N:22]([CH3:32])[CH3:21])=[CH:24][CH:25]=3)=[CH:16][CH:15]=2)[C:6]2[C:11]([CH:12]=1)=[CH:10][C:9]([NH:13][C:27](=[O:28])[C:26]1[CH:25]=[CH:24][C:23]([N:22]([CH3:21])[CH3:32])=[CH:31][CH:30]=1)=[CH:8][CH:7]=2)(=[O:3])[CH3:2]Compound 372 was prepared according to the procedure described in Scheme IV from 2-acetyl-5-amino-1-(4-aminophenyl)indole and 4-dimethylaminobenzoate. [M+H]+ calcd for C34H33N5O3: 560.26; found: 560.02.
読み込み中…